中重度创伤性脑损伤住院成人癫痫预防指南:神经重症学会临床实践指南
该指南由神经重症学会制定,针对中重度创伤性脑损伤(TBI)住院成人,系统评价并Meta分析了预防性抗癫痫发作药物(ASM)的使用与否、药物选择(左乙拉西坦 vs 苯妥英/磷苯妥英)及疗程(>7天 vs ≤7天)三个PICO问题。共33篇文章构成推荐基础。结果显示:ASM与不用ASM在早期癫痫、晚期癫痫、不良事件或死亡率上未检测到显著正负效应;苯妥英/磷苯妥英与左乙拉西坦在早期癫痫或死亡率上无显著差异,但点估计提示左乙拉西坦晚期癫痫和不良事件更少;长疗程与短疗程在早期或晚期癫痫上无显著差异,但延长使用认知结局和不良事件似乎更差。基于GRADE标准,指南建议ASM可用或不用(弱推荐,低质量证据);若使用,建议左乙拉西坦优于苯妥英/磷苯妥英(弱推荐,极低质量证据),并建议短疗程(≤7天,弱推荐,低质量证据)。
要点
- 中重度TBI住院成人,预防性ASM可用或不用(弱推荐,低质量证据)。
- 若使用ASM,建议左乙拉西坦优于苯妥英/磷苯妥英(弱推荐,极低质量证据)。
- 若使用ASM,建议短疗程≤7天(弱推荐,低质量证据)。
- ASM与不用ASM在早期癫痫、晚期癫痫、不良事件或死亡率上未检测到显著正负效应。
- 长疗程(>7天)与短疗程(≤7天)在早期或晚期癫痫上无显著差异,但认知结局和不良事件似乎更差。
适用人群与场景
- 中重度创伤性脑损伤成人住院患者,具备急性影像学发现且需要住院。
- 无临床或脑电图癫痫发作史的患者。
处置流程与药物剂量
- 预防性ASM可用或不用(弱推荐,低质量证据)。
- 若使用ASM,建议左乙拉西坦优于苯妥英/磷苯妥英(弱推荐,极低质量证据)。
- 若使用ASM,建议短疗程≤7天(弱推荐,低质量证据)。
研究设计与关键结果
- 系统评价与Meta分析共纳入33篇文章构成推荐基础,初始文献检索得到1998篇文章。
- PICO 1:ASM与不用ASM在早期癫痫、晚期癫痫、不良事件或死亡率上未检测到显著正负效应。
- PICO 2:苯妥英/磷苯妥英与左乙拉西坦在早期癫痫或死亡率上未检测到显著正负效应,但点估计提示左乙拉西坦晚期癫痫更少、不良事件更少。
- PICO 3:长疗程(>7天)与短疗程(≤7天)在早期或晚期癫痫上无显著差异,但延长使用认知结局和不良事件似乎更差。
证据类型、等级与局限
- 证据类型:临床实践指南,基于系统评价与Meta分析,采用GRADE方法生成推荐。
- 推荐强度与证据质量:ASM可用或不用(弱推荐,低质量证据);左乙拉西坦优于苯妥英/磷苯妥英(弱推荐,极低质量证据);短疗程≤7天(弱推荐,低质量证据)。
- 局限:原文未报告局限性
对床旁实践的改变
- 该指南支持在中重度TBI住院成人中个体化决定是否启动预防性ASM,而非一律使用(弱推荐,低质量证据)。
- 若决定使用ASM,作者建议优先选择左乙拉西坦而非苯妥英/磷苯妥英(弱推荐,极低质量证据)。
- 若决定使用ASM,作者建议疗程不超过7天(弱推荐,低质量证据),因延长使用认知结局和不良事件似乎更差。
指南或共识出处
- 指南名称:Guidelines for Seizure Prophylaxis in Adults Hospitalized with Moderate-Severe Traumatic Brain Injury: A Clinical Practice Guideline for Health Care Professionals from the Neurocritical Care Society
- 发布机构:神经重症学会(Neurocritical Care Society)
- 发表期刊:Neurocrit Care
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: There is practice heterogeneity in the use, type, and duration of prophylactic antiseizure medications (ASMs) in patients with moderate-severe traumatic brain injury (TBI).
METHODS: We conducted a systematic review and meta-analysis of articles assessing ASM prophylaxis in adults with moderate-severe TBI (acute radiographic findings and requiring hospitalization). The population, intervention, comparator, and outcome (PICO) questions were as follows: (1) Should ASM versus no ASM be used in patients with moderate-severe TBI and no history of clinical or electrographic seizures? (2) If an ASM is used, should levetiracetam (LEV) or phenytoin/fosphenytoin (PHT/fPHT) be preferentially used? (3) If an ASM is used, should a long versus short (> 7 vs. ≤ 7 days) duration of prophylaxis be used? The main outcomes were early seizure, late seizure, adverse events, mortality, and functional outcomes. We used Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology to generate recommendations.
RESULTS: The initial literature search yielded 1998 articles, of which 33 formed the basis of the recommendations: PICO 1: We did not detect any significant positive or negative effect of ASM compared to no ASM on the outcomes of early seizure, late seizure, adverse events, or mortality. PICO 2: We did not detect any significant positive or negative effect of PHT/fPHT compared to LEV for early seizures or mortality, though point estimates suggest fewer late seizures and fewer adverse events with LEV. PICO 3: There were no significant differences in early or late seizures with longer versus shorter ASM use, though cognitive outcomes and adverse events appear worse with protracted use.
CONCLUSIONS: Based on GRADE criteria, we suggest that ASM or no ASM may be used in patients hospitalized with moderate-severe TBI (weak recommendation, low quality of evidence). If used, we suggest LEV over PHT/fPHT (weak recommendation, very low quality of evidence) for a short duration (≤ 7 days, weak recommendation, low quality of evidence).
参考来源
- Frontera JA, Gilmore EJ, Johnson EL, et al. Guidelines for Seizure Prophylaxis in Adults Hospitalized with Moderate-Severe Traumatic Brain Injury: A Clinical Practice Guideline for Health Care Professionals from the Neurocritical Care Society. Neurocrit Care. 2024. PMID: 38316735. doi:10.1007/s12028-023-01907-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。